A Cohort Establishment Study of Total Management of Ovarian Cancer

Sponsor
Sichuan Cancer Hospital and Research Institute (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06018935
Collaborator
(none)
500
24

Study Details

Study Description

Brief Summary

A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

Condition or Disease Intervention/Treatment Phase
  • Other: No intervention

Detailed Description

  1. To investigate the effects of surgery, chemotherapy, maintenance therapy and related factors on the prognosis and quality of life of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer);

  2. To study the postoperative recovery of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer), perioperative complications, adverse reactions after chemotherapy, adverse reactions during targeted drug maintenance therapy, and explore possible effective preventive measures;

  3. The prognostic factors of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) were analyzed;

  4. To study the efficacy and safety of PARPi in clinical application in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

Study Design

Study Type:
Observational
Anticipated Enrollment :
500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Cohort Establishment Study of Total Management of Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer)
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Sep 1, 2025

Outcome Measures

Primary Outcome Measures

  1. Progress Freesurvival (PFS) [Average six months after study completion.]

    The time from the start of treatment until the patient progresses further or dies.

  2. Overall Survival (OS) [Average six months after study completion.]

    Measure the time from the start of treatment to the time of death.

Secondary Outcome Measures

  1. Occurrence of adverse reactions [Average six months after study completion.]

    All adverse events were recorded.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital;

  2. Can cooperate with later follow-up.

Exclusion Criteria:
  1. Patients with other malignant tumors or previous history of other malignant tumors;

  2. Have cognitive impairment.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Sichuan Cancer Hospital and Research Institute

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dengfeng Wang, Deputy chief, Sichuan Cancer Hospital and Research Institute
ClinicalTrials.gov Identifier:
NCT06018935
Other Study ID Numbers:
  • LCATM202304
First Posted:
Aug 31, 2023
Last Update Posted:
Aug 31, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dengfeng Wang, Deputy chief, Sichuan Cancer Hospital and Research Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 31, 2023